Cellectis Announces Upcoming Presentations at the 56th Annual Meeting of the American Society of Hematology (ASH)
Published on November 24, 2014
Paris, November 24, 2014 - Cellectis SA (Alternext: ALCLS.PA), a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART-cells (UCART), today announced that three abstracts on the Company’s CART cell development programs were accepted for presentation at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Francisco, December 6-9, 2014.
The abstracts are listed below and available on the ASH conference website at:
https://ash.confex.com/ash/2014/webprogram/start.html
Poster Presentations
Title: “Multiplex Genome Editing As a Platform for “Off-the-Shelf” Adoptive CAR T-Cell Immunotherapies”
• Abstract Number: 1111
• Date: Saturday, December 6, 2014
• Presentation Time: 5:30 PM - 7:30 PM PST
Title: “Allogeneic T-Cells Targeting CD123 for Adoptive Immunotherapy of Acute Myeloid Leukemia (AML)”
• Abstract Number: 1116
• Date: Saturday, December 6, 2014
• Presentation Time: 5:30 PM - 7:30 PM PST
Title: “In Vivo Proof of Concept of Activity and Safety of UCART19, an Allogeneic ‘Off-the-Shelf’ Adoptive T-Cell Immunotherapy against CD19+ B-Cell Leukemias”
• Abstract Number: 4689
• Date: Monday, December 8, 2014
• Presentation Time: 6:00 PM - 8:00 PM PST